Deficit di alfa-1 antitripsina: Diagnosi e terapia

Translated title of the contribution: Alpha-1 antitrypsin deficiency: Diagnosis and treatment

Bruno Balbi, Luciano Corda, Maurizio Luisetti

Research output: Contribution to journalArticle

Abstract

Alpha-1 antitrypsin (AAT) deficiency (D) is an autosomic codominant genetic condition associated with an increased risk of lung and liver disease. Lung disease is usually seen as an emphysema developing during the 4th or 5th decade, that may be associated with disseminated bronchiectasis, or it may be more similar to a COPD or, more rarely, to asthma. Liver disease can be seen within the first year of life as hepatic cholestasis, or later on during the 5th or 6th decade as a chronic hepatic disorder or liver cirrhosis or even hepatic cancer. Gene-environment interaction is crucial in AATD associated clinical manifestations. The risk of lung diseases is increased manifold in smokers. Life-long non smokers can be asymptomatic and without any evidence of lung disease for the whole life. Diagnosis is based on the determination of AAT plasma levels followed, in the case of values lower than normal, by genotyping. Pharmacological treatment of lung disease (COPD) associated with AATD comprises AAT replacement therapy, i.e. a weekly i.v. infusion of AAT from the blood donor pool. Replacement therapy is considered able to slow the annual decline of lung function, particularly accelerated in AATD. Pulmonary rehabilitation, lung or liver transplantation are the other non-pharmacological options in the management of AATD associated diseases.

Original languageItalian
JournalMultidisciplinary Respiratory Medicine
Volume5
Issue numberSUPPL. 3
Publication statusPublished - 2010

Fingerprint

alpha 1-Antitrypsin Deficiency
Lung Diseases
alpha 1-Antitrypsin
Lung Transplantation
Liver Cirrhosis
Chronic Obstructive Pulmonary Disease
Liver Diseases
Therapeutics
Gene-Environment Interaction
Bronchiectasis
Cholestasis
Emphysema
Liver Neoplasms
Blood Donors
Liver Transplantation
Reference Values
Rehabilitation
Asthma
Autosomal Recessive alpha-1-Antitrypsin Deficiency
Pharmacology

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Deficit di alfa-1 antitripsina : Diagnosi e terapia. / Balbi, Bruno; Corda, Luciano; Luisetti, Maurizio.

In: Multidisciplinary Respiratory Medicine, Vol. 5, No. SUPPL. 3, 2010.

Research output: Contribution to journalArticle

Balbi, Bruno ; Corda, Luciano ; Luisetti, Maurizio. / Deficit di alfa-1 antitripsina : Diagnosi e terapia. In: Multidisciplinary Respiratory Medicine. 2010 ; Vol. 5, No. SUPPL. 3.
@article{d78713817ae249d697dead61529a7a92,
title = "Deficit di alfa-1 antitripsina: Diagnosi e terapia",
abstract = "Alpha-1 antitrypsin (AAT) deficiency (D) is an autosomic codominant genetic condition associated with an increased risk of lung and liver disease. Lung disease is usually seen as an emphysema developing during the 4th or 5th decade, that may be associated with disseminated bronchiectasis, or it may be more similar to a COPD or, more rarely, to asthma. Liver disease can be seen within the first year of life as hepatic cholestasis, or later on during the 5th or 6th decade as a chronic hepatic disorder or liver cirrhosis or even hepatic cancer. Gene-environment interaction is crucial in AATD associated clinical manifestations. The risk of lung diseases is increased manifold in smokers. Life-long non smokers can be asymptomatic and without any evidence of lung disease for the whole life. Diagnosis is based on the determination of AAT plasma levels followed, in the case of values lower than normal, by genotyping. Pharmacological treatment of lung disease (COPD) associated with AATD comprises AAT replacement therapy, i.e. a weekly i.v. infusion of AAT from the blood donor pool. Replacement therapy is considered able to slow the annual decline of lung function, particularly accelerated in AATD. Pulmonary rehabilitation, lung or liver transplantation are the other non-pharmacological options in the management of AATD associated diseases.",
keywords = "Alpha-1 antitrypsin deficiency, Bronchodilator therapy, COPD, Hepatic diseases, Liver transplantation, Lung transplantation, Pulmonary rehabilitation, Replacement therapy",
author = "Bruno Balbi and Luciano Corda and Maurizio Luisetti",
year = "2010",
language = "Italian",
volume = "5",
journal = "Multidisciplinary Respiratory Medicine",
issn = "1828-695X",
publisher = "BioMed Central Ltd.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Deficit di alfa-1 antitripsina

T2 - Diagnosi e terapia

AU - Balbi, Bruno

AU - Corda, Luciano

AU - Luisetti, Maurizio

PY - 2010

Y1 - 2010

N2 - Alpha-1 antitrypsin (AAT) deficiency (D) is an autosomic codominant genetic condition associated with an increased risk of lung and liver disease. Lung disease is usually seen as an emphysema developing during the 4th or 5th decade, that may be associated with disseminated bronchiectasis, or it may be more similar to a COPD or, more rarely, to asthma. Liver disease can be seen within the first year of life as hepatic cholestasis, or later on during the 5th or 6th decade as a chronic hepatic disorder or liver cirrhosis or even hepatic cancer. Gene-environment interaction is crucial in AATD associated clinical manifestations. The risk of lung diseases is increased manifold in smokers. Life-long non smokers can be asymptomatic and without any evidence of lung disease for the whole life. Diagnosis is based on the determination of AAT plasma levels followed, in the case of values lower than normal, by genotyping. Pharmacological treatment of lung disease (COPD) associated with AATD comprises AAT replacement therapy, i.e. a weekly i.v. infusion of AAT from the blood donor pool. Replacement therapy is considered able to slow the annual decline of lung function, particularly accelerated in AATD. Pulmonary rehabilitation, lung or liver transplantation are the other non-pharmacological options in the management of AATD associated diseases.

AB - Alpha-1 antitrypsin (AAT) deficiency (D) is an autosomic codominant genetic condition associated with an increased risk of lung and liver disease. Lung disease is usually seen as an emphysema developing during the 4th or 5th decade, that may be associated with disseminated bronchiectasis, or it may be more similar to a COPD or, more rarely, to asthma. Liver disease can be seen within the first year of life as hepatic cholestasis, or later on during the 5th or 6th decade as a chronic hepatic disorder or liver cirrhosis or even hepatic cancer. Gene-environment interaction is crucial in AATD associated clinical manifestations. The risk of lung diseases is increased manifold in smokers. Life-long non smokers can be asymptomatic and without any evidence of lung disease for the whole life. Diagnosis is based on the determination of AAT plasma levels followed, in the case of values lower than normal, by genotyping. Pharmacological treatment of lung disease (COPD) associated with AATD comprises AAT replacement therapy, i.e. a weekly i.v. infusion of AAT from the blood donor pool. Replacement therapy is considered able to slow the annual decline of lung function, particularly accelerated in AATD. Pulmonary rehabilitation, lung or liver transplantation are the other non-pharmacological options in the management of AATD associated diseases.

KW - Alpha-1 antitrypsin deficiency

KW - Bronchodilator therapy

KW - COPD

KW - Hepatic diseases

KW - Liver transplantation

KW - Lung transplantation

KW - Pulmonary rehabilitation

KW - Replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=77958108555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958108555&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:77958108555

VL - 5

JO - Multidisciplinary Respiratory Medicine

JF - Multidisciplinary Respiratory Medicine

SN - 1828-695X

IS - SUPPL. 3

ER -